Patent · US Active

Anti-ILT4 antibodies and antigen-binding fragments

US11053315B2 · kind B2 · utility

1Cited by

36References

22Claims

0Family size

Assignees

Merck Sharp & Dohme LLC · US
Agenus Inc. · US

Inventors

Barbara Joyce-Shaikh · San Jose, US
Luis A. Zuniga · Mountain View, US
Milan Blanusa · Jena, DE
Andrea Schuster · Bayreuth, DE
Kornelia Schultze · Jena, DE

Key dates

Filing date	Apr 5, 2018
Grant date	Jul 6, 2021
Priority date	—
Expiry date	Jun 21, 2038

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention provides antibodies and antigen-binding fragments thereof that bind to ILT4 (immunoglobulin-like transcript 4) and combinations thereof, e.g., with an anti-PD1 antibody. Also provided are methods of use thereof, for example, for treating or preventing cancer in a subject; and methods of making such antibodies and fragments.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.